img

Global Cancer Immunotherapy Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Cancer Immunotherapy Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Immunotherapy, also called biologic therapy, is a type of cancer treatment that boosts the body's natural defenses to fight cancer.
Due to the COVID-19 pandemic, the global Cancer Immunotherapy market size was US$ 75950 million in 2022 and is forecast to a readjusted size of US$ 135140 million by 2034 with a CAGR of 8.1% during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Monoclonal Antibodies accounting for % of the Cancer Immunotherapy global market in 2022, is projected to value US$ million by 2034, growing at a revised % CAGR from 2024 to 2034. While Lung Cancer segment is altered to an % CAGR throughout this forecast period.
The global key companies of Cancer Immunotherapy include Amgen, AstraZeneca, Roche, Bayer, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis and Pfizer, etc. In 2022, the global top five players had a share approximately % in terms of revenue.
The United States Cancer Immunotherapy market size was US$ million in 2022, while China size was US$ million. The proportion of the United States was % in 2022, while China percentage was %, and it is predicted that China share will reach % in 2034, trailing a CAGR of % through the analysis period. As for the Europe Cancer Immunotherapy landscape, Germany is projected to reach US$ million by 2034. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Cancer Immunotherapy market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Cancer Immunotherapy market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Cancer Immunotherapy market. Readers of the report can become informed about current and future trends of the global Cancer Immunotherapy market and how they will impact market growth during the forecast period.



By Company


Amgen
AstraZeneca
Roche
Bayer
Bristol-Myers Squibb
Eli Lilly
Merck
Novartis
Pfizer
Segment by Type
Monoclonal Antibodies
Immune Checkpoint Inhibitors
Immune System Modulators
Cancer Vaccines

Segment by Application


Lung Cancer
Breast Cancer
Colorectal Cancer
Melanoma
Prostate Cancer
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on.
Chapter 2Revenue of Cancer Immunotherapy in global and regional level.
Chapter 3Detailed analysis of Cancer Immunotherapy companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8Asia Pacific by type, by application and by region, revenue for each segment.
Chapter 9Latin America by type, by application and by country, revenue for each segment.
Chapter 10Middle East and Africa, by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Cancer Immunotherapy revenue, gross margin, and recent development, etc.
Chapter 12Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 13Research Findings and Conclusion

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Cancer Immunotherapy Market Size Growth Rate by Type: 2018 VS 2022 VS 2034
1.2.2 Monoclonal Antibodies
1.2.3 Immune Checkpoint Inhibitors
1.2.4 Immune System Modulators
1.2.5 Cancer Vaccines
1.3 Market by Application
1.3.1 Global Cancer Immunotherapy Market Growth Rate by Application: 2018 VS 2022 VS 2034
1.3.2 Lung Cancer
1.3.3 Breast Cancer
1.3.4 Colorectal Cancer
1.3.5 Melanoma
1.3.6 Prostate Cancer
1.3.7 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Market Perspective
2.1 Global Cancer Immunotherapy Market Size (2018-2034)
2.2 Cancer Immunotherapy Market Size across Key Geographies Worldwide: 2018 VS 2022 VS 2034
2.3 Global Cancer Immunotherapy Market Size by Region (2018-2024)
2.4 Global Cancer Immunotherapy Market Size Forecast by Region (2024-2034)
2.5 Global Top 10 Cancer Immunotherapy Countries Ranking by Market Size
3 Cancer Immunotherapy Competitive by Company
3.1 Global Cancer Immunotherapy Revenue by Players
3.1.1 Global Cancer Immunotherapy Revenue by Players (2018-2024)
3.1.2 Global Cancer Immunotherapy Market Share by Players (2018-2024)
3.2 Global Cancer Immunotherapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Company Covered: Ranking by Cancer Immunotherapy Revenue
3.4 Global Cancer Immunotherapy Market Concentration Ratio
3.4.1 Global Cancer Immunotherapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cancer Immunotherapy Revenue in 2022
3.5 Global Key Players of Cancer Immunotherapy Head office and Area Served
3.6 Global Key Players of Cancer Immunotherapy, Product and Application
3.7 Global Key Players of Cancer Immunotherapy, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Cancer Immunotherapy Breakdown Data by Type
4.1 Global Cancer Immunotherapy Historic Revenue by Type (2018-2024)
4.2 Global Cancer Immunotherapy Forecasted Revenue by Type (2024-2034)
5 Global Cancer Immunotherapy Breakdown Data by Application
5.1 Global Cancer Immunotherapy Historic Market Size by Application (2018-2024)
5.2 Global Cancer Immunotherapy Forecasted Market Size by Application (2024-2034)
6 North America
6.1 North America Cancer Immunotherapy Revenue by Company (2021-2024)
6.2 North America Cancer Immunotherapy Revenue by Type (2018-2034)
6.3 North America Cancer Immunotherapy Revenue by Application (2018-2034)
6.4 North America Cancer Immunotherapy Revenue by Country (2018-2034)
6.4.1 U.S.
6.4.2 Canada
7 Europe
7.1 Europe Cancer Immunotherapy Revenue by Company (2021-2024)
7.2 Europe Cancer Immunotherapy Revenue by Type (2018-2034)
7.3 Europe Cancer Immunotherapy Revenue by Application (2018-2034)
7.4 Europe Cancer Immunotherapy Revenue by Country (2018-2034)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
8 Asia Pacific
8.1 Asia Pacific Cancer Immunotherapy Revenue by Company (2021-2024)
8.2 Asia Pacific Cancer Immunotherapy Revenue by Type (2018-2034)
8.3 Asia Pacific Cancer Immunotherapy Revenue by Application (2018-2034)
8.4 Asia Pacific Cancer Immunotherapy Revenue by Region (2018-2034)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 India
8.4.5 Australia
8.4.6 Taiwan
8.4.7 Indonesia
8.4.8 Thailand
8.4.9 Malaysia
8.4.10 Philippines
8.4.11 Vietnam
9 Latin America
9.1 Latin America Cancer Immunotherapy Revenue by Company (2021-2024)
9.2 Latin America Cancer Immunotherapy Revenue by Type (2018-2034)
9.3 Latin America Cancer Immunotherapy Revenue by Application (2018-2034)
9.4 Latin America Cancer Immunotherapy Revenue by Country (2018-2034)
9.4.1 Mexico
9.4.2 Brazil
9.4.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Cancer Immunotherapy Revenue by Company (2021-2024)
10.2 Middle East and Africa Cancer Immunotherapy Revenue by Type (2018-2034)
10.3 Middle East and Africa Cancer Immunotherapy Revenue by Application (2018-2034)
10.4 Middle East and Africa Cancer Immunotherapy Revenue by Country (2018-2034)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 U.A.E
11 Company Profiles
11.1 Amgen
11.1.1 Amgen Company Details
11.1.2 Amgen Business Overview
11.1.3 Amgen Cancer Immunotherapy Products and Services
11.1.4 Amgen Cancer Immunotherapy Revenue in Cancer Immunotherapy Business (2018-2024)
11.1.5 Amgen Cancer Immunotherapy SWOT Analysis
11.1.6 Amgen Recent Development
11.2 AstraZeneca
11.2.1 AstraZeneca Company Details
11.2.2 AstraZeneca Business Overview
11.2.3 AstraZeneca Cancer Immunotherapy Products and Services
11.2.4 AstraZeneca Cancer Immunotherapy Revenue in Cancer Immunotherapy Business (2018-2024)
11.2.5 AstraZeneca Cancer Immunotherapy SWOT Analysis
11.2.6 AstraZeneca Recent Development
11.3 Roche
11.3.1 Roche Company Details
11.3.2 Roche Business Overview
11.3.3 Roche Cancer Immunotherapy Products and Services
11.3.4 Roche Cancer Immunotherapy Revenue in Cancer Immunotherapy Business (2018-2024)
11.3.5 Roche Cancer Immunotherapy SWOT Analysis
11.3.6 Roche Recent Development
11.4 Bayer
11.4.1 Bayer Company Details
11.4.2 Bayer Business Overview
11.4.3 Bayer Cancer Immunotherapy Products and Services
11.4.4 Bayer Cancer Immunotherapy Revenue in Cancer Immunotherapy Business (2018-2024)
11.4.5 Bayer Cancer Immunotherapy SWOT Analysis
11.4.6 Bayer Recent Development
11.5 Bristol-Myers Squibb
11.5.1 Bristol-Myers Squibb Company Details
11.5.2 Bristol-Myers Squibb Business Overview
11.5.3 Bristol-Myers Squibb Cancer Immunotherapy Products and Services
11.5.4 Bristol-Myers Squibb Cancer Immunotherapy Revenue in Cancer Immunotherapy Business (2018-2024)
11.5.5 Bristol-Myers Squibb Cancer Immunotherapy SWOT Analysis
11.5.6 Bristol-Myers Squibb Recent Development
11.6 Eli Lilly
11.6.1 Eli Lilly Company Details
11.6.2 Eli Lilly Business Overview
11.6.3 Eli Lilly Cancer Immunotherapy Products and Services
11.6.4 Eli Lilly Cancer Immunotherapy Revenue in Cancer Immunotherapy Business (2018-2024)
11.6.5 Eli Lilly Cancer Immunotherapy SWOT Analysis
11.6.6 Eli Lilly Recent Development
11.7 Merck
11.7.1 Merck Company Details
11.7.2 Merck Business Overview
11.7.3 Merck Cancer Immunotherapy Products and Services
11.7.4 Merck Cancer Immunotherapy Revenue in Cancer Immunotherapy Business (2018-2024)
11.7.5 Merck Cancer Immunotherapy SWOT Analysis
11.7.6 Merck Recent Development
11.8 Novartis
11.8.1 Novartis Company Details
11.8.2 Novartis Business Overview
11.8.3 Novartis Cancer Immunotherapy Products and Services
11.8.4 Novartis Cancer Immunotherapy Revenue in Cancer Immunotherapy Business (2018-2024)
11.8.5 Novartis Cancer Immunotherapy SWOT Analysis
11.8.6 Novartis Recent Development
11.9 Pfizer
11.9.1 Pfizer Company Details
11.9.2 Pfizer Business Overview
11.9.3 Pfizer Cancer Immunotherapy Products and Services
11.9.4 Pfizer Cancer Immunotherapy Revenue in Cancer Immunotherapy Business (2018-2024)
11.9.5 Pfizer Cancer Immunotherapy SWOT Analysis
11.9.6 Pfizer Recent Development
12 Cancer Immunotherapy Market Dynamics
12.1 Cancer Immunotherapy Industry Trends
12.2 Cancer Immunotherapy Market Drivers
12.3 Cancer Immunotherapy Market Challenges
12.4 Cancer Immunotherapy Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details

List of Figure

List of Tables
Table 1. Global Cancer Immunotherapy Market Size Growth Rate (CAGR) by Type (US$ Million), 2018 VS 2022 VS 2034
Table 2. Key Players of Monoclonal Antibodies
Table 3. Key Players of Immune Checkpoint Inhibitors
Table 4. Key Players of Immune System Modulators
Table 5. Key Players of Cancer Vaccines
Table 6. Global Cancer Immunotherapy Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2034
Table 7. Global Cancer Immunotherapy Market Size (US$ Million) Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2034
Table 8. Global Cancer Immunotherapy Revenue by Region (2018-2024) & (US$ Million)
Table 9. Global Cancer Immunotherapy Revenue Forecast by Region (2024-2034) & (US$ Million)
Table 10. Global Cancer Immunotherapy Market Size of Top 10 Countries, 2018 VS 2022 VS 2034, (US$ Million)
Table 11. Global Cancer Immunotherapy Revenue by Players (2018-2024) & (US$ Million)
Table 12. Global Cancer Immunotherapy Market Share by Players (2018-2024)
Table 13. Global Top Cancer Immunotherapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Immunotherapy as of 2022)
Table 14. Ranking of Global Top Cancer Immunotherapy Companies by Revenue (US$ Million) in 2022
Table 15. Global 5 Largest Players Market Share by Cancer Immunotherapy Revenue (CR5 and HHI) & (2018-2024)
Table 16. Global Key Players of Cancer Immunotherapy, Headquarters and Area Served
Table 17. Global Key Players of Cancer Immunotherapy, Product and Application
Table 18. Global Key Players of Cancer Immunotherapy, Date of Enter into This Industry
Table 19. Mergers & Acquisitions, Expansion Plans
Table 20. Global Cancer Immunotherapy Market Size by Type (2018-2024) & (US$ Million)
Table 21. Global Cancer Immunotherapy Revenue Market Share by Type (2018-2024)
Table 22. Global Cancer Immunotherapy Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 23. Global Cancer Immunotherapy Revenue Market Share by Type (2024-2034)
Table 24. Global Cancer Immunotherapy Market Size by Application (2018-2024) & (US$ Million)
Table 25. Global Cancer Immunotherapy Revenue Market Share by Application (2018-2024)
Table 26. Global Cancer Immunotherapy Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 27. Global Cancer Immunotherapy Revenue Market Share by Application (2024-2034)
Table 28. North America Cancer Immunotherapy Revenue by Company (2021-2024) & (US$ Million)
Table 29. North America Cancer Immunotherapy Revenue by Type (2018-2024) & (US$ Million)
Table 30. North America Cancer Immunotherapy Revenue by Type (2024-2034) & (US$ Million)
Table 31. North America Cancer Immunotherapy Revenue by Application (2018-2024) & (US$ Million)
Table 32. North America Cancer Immunotherapy Revenue by Application (2024-2034) & (US$ Million)
Table 33. North America Cancer Immunotherapy Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 34. North America Cancer Immunotherapy Revenue by Country (2018-2024) & (US$ Million)
Table 35. North America Cancer Immunotherapy Revenue by Country (2024-2034) & (US$ Million)
Table 36. Europe Cancer Immunotherapy Revenue by Company (2021-2024) & (US$ Million)
Table 37. Europe Cancer Immunotherapy Revenue by Type (2018-2024) & (US$ Million)
Table 38. Europe Cancer Immunotherapy Revenue by Type (2024-2034) & (US$ Million)
Table 39. Europe Cancer Immunotherapy Revenue by Application (2018-2024) & (US$ Million)
Table 40. Europe Cancer Immunotherapy Revenue by Application (2024-2034) & (US$ Million)
Table 41. Europe Cancer Immunotherapy Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 42. Europe Cancer Immunotherapy Revenue by Country (2018-2024) & (US$ Million)
Table 43. Europe Cancer Immunotherapy Revenue by Country (2024-2034) & (US$ Million)
Table 44. Asia Pacific Cancer Immunotherapy Revenue by Company (2021-2024) & (US$ Million)
Table 45. Asia Pacific Cancer Immunotherapy Revenue by Type (2018-2024) & (US$ Million)
Table 46. Asia Pacific Cancer Immunotherapy Revenue by Type (2024-2034) & (US$ Million)
Table 47. Asia Pacific Cancer Immunotherapy Revenue by Application (2018-2024) & (US$ Million)
Table 48. Asia Pacific Cancer Immunotherapy Revenue by Application (2024-2034) & (US$ Million)
Table 49. Asia-Pacific Cancer Immunotherapy Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2034
Table 50. Asia Pacific Cancer Immunotherapy Revenue by Region (2018-2024) & (US$ Million)
Table 51. Asia Pacific Cancer Immunotherapy Revenue by Region (2024-2034) & (US$ Million)
Table 52. Latin America Cancer Immunotherapy Revenue by Company (2021-2024) & (US$ Million)
Table 53. Latin America Cancer Immunotherapy Revenue by Type (2018-2024) & (US$ Million)
Table 54. Latin America Cancer Immunotherapy Revenue by Type (2024-2034) & (US$ Million)
Table 55. Latin America Cancer Immunotherapy Revenue by Application (2018-2024) & (US$ Million)
Table 56. Latin America Cancer Immunotherapy Revenue by Application (2024-2034) & (US$ Million)
Table 57. Latin America Cancer Immunotherapy Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 58. Latin America Cancer Immunotherapy Revenue by Country (2018-2024) & (US$ Million)
Table 59. Latin America Cancer Immunotherapy Revenue by Country (2024-2034) & (US$ Million)
Table 60. Middle East and Africa Cancer Immunotherapy Revenue by Company (2021-2024) & (US$ Million)
Table 61. Middle East and Africa Cancer Immunotherapy Revenue by Type (2018-2024) & (US$ Million)
Table 62. Middle East and Africa Cancer Immunotherapy Revenue by Type (2024-2034) & (US$ Million)
Table 63. Middle East and Africa Cancer Immunotherapy Revenue by Application (2018-2024) & (US$ Million)
Table 64. Middle East and Africa Cancer Immunotherapy Revenue by Application (2024-2034) & (US$ Million)
Table 65. Middle East and Africa Cancer Immunotherapy Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 66. Middle East and Africa Cancer Immunotherapy Revenue by Country (2018-2024) & (US$ Million)
Table 67. Middle East and Africa Cancer Immunotherapy Revenue by Country (2024-2034) & (US$ Million)
Table 68. Amgen Company Details
Table 69. Amgen Business Overview
Table 70. Amgen Cancer Immunotherapy Product and Services
Table 71. Amgen Cancer Immunotherapy Revenue in Cancer Immunotherapy Business (2018-2024) & (US$ Million)
Table 72. Amgen Cancer Immunotherapy SWOT Analysis
Table 73. Amgen Recent Development
Table 74. AstraZeneca Company Details
Table 75. AstraZeneca Business Overview
Table 76. AstraZeneca Cancer Immunotherapy Product and Services
Table 77. AstraZeneca Cancer Immunotherapy Revenue in Cancer Immunotherapy Business (2018-2024) & (US$ Million)
Table 78. AstraZeneca Cancer Immunotherapy SWOT Analysis
Table 79. AstraZeneca Recent Development
Table 80. Roche Company Details
Table 81. Roche Business Overview
Table 82. Roche Cancer Immunotherapy Product and Services
Table 83. Roche Cancer Immunotherapy Revenue in Cancer Immunotherapy Business (2018-2024) & (US$ Million)
Table 84. Roche Cancer Immunotherapy SWOT Analysis
Table 85. Roche Recent Development
Table 86. Bayer Company Details
Table 87. Bayer Business Overview
Table 88. Bayer Cancer Immunotherapy Product and Services
Table 89. Bayer Cancer Immunotherapy Revenue in Cancer Immunotherapy Business (2018-2024) & (US$ Million)
Table 90. Bayer Cancer Immunotherapy SWOT Analysis
Table 91. Bayer Recent Development
Table 92. Bristol-Myers Squibb Company Details
Table 93. Bristol-Myers Squibb Business Overview
Table 94. Bristol-Myers Squibb Cancer Immunotherapy Product and Services
Table 95. Bristol-Myers Squibb Cancer Immunotherapy Revenue in Cancer Immunotherapy Business (2018-2024) & (US$ Million)
Table 96. Bristol-Myers Squibb Cancer Immunotherapy SWOT Analysis
Table 97. Bristol-Myers Squibb Recent Development
Table 98. Eli Lilly Company Details
Table 99. Eli Lilly Business Overview
Table 100. Eli Lilly Cancer Immunotherapy Product and Services
Table 101. Eli Lilly Cancer Immunotherapy Revenue in Cancer Immunotherapy Business (2018-2024) & (US$ Million)
Table 102. Eli Lilly Cancer Immunotherapy SWOT Analysis
Table 103. Eli Lilly Recent Development
Table 104. Merck Company Details
Table 105. Merck Business Overview
Table 106. Merck Cancer Immunotherapy Product and Services
Table 107. Merck Cancer Immunotherapy Revenue in Cancer Immunotherapy Business (2018-2024) & (US$ Million)
Table 108. Merck Cancer Immunotherapy SWOT Analysis
Table 109. Merck Recent Development
Table 110. Novartis Company Details
Table 111. Novartis Business Overview
Table 112. Novartis Cancer Immunotherapy Product and Services
Table 113. Novartis Cancer Immunotherapy Revenue in Cancer Immunotherapy Business (2018-2024) & (US$ Million)
Table 114. Novartis Cancer Immunotherapy SWOT Analysis
Table 115. Novartis Recent Development
Table 116. Pfizer Company Details
Table 117. Pfizer Business Overview
Table 118. Pfizer Cancer Immunotherapy Product and Services
Table 119. Pfizer Cancer Immunotherapy Revenue in Cancer Immunotherapy Business (2018-2024) & (US$ Million)
Table 120. Pfizer Cancer Immunotherapy SWOT Analysis
Table 121. Pfizer Recent Development
Table 122. Cancer Immunotherapy Market Trends
Table 123. Cancer Immunotherapy Market Drivers
Table 124. Cancer Immunotherapy Market Challenges
Table 125. Cancer Immunotherapy Market Restraints
Table 126. Research Programs/Design for This Report
Table 127. Key Data Information from Secondary Sources
Table 128. Key Data Information from Primary Sources
List of Figures
Figure 1. Cancer Immunotherapy Product Picture
Figure 2. Global Cancer Immunotherapy Market Size by Type (US$ Million): 2018 VS 2022 VS 2034
Figure 3. Global Cancer Immunotherapy Market Share by Type: 2022 VS 2034
Figure 4. Monoclonal Antibodies Features
Figure 5. Immune Checkpoint Inhibitors Features
Figure 6. Immune System Modulators Features
Figure 7. Cancer Vaccines Features
Figure 8. Global Cancer Immunotherapy Market Size by Application (US$ Million): 2018 VS 2022 VS 2034
Figure 9. Global Cancer Immunotherapy Market Share by Application: 2022 VS 2034
Figure 10. Lung Cancer
Figure 11. Breast Cancer
Figure 12. Colorectal Cancer
Figure 13. Melanoma
Figure 14. Prostate Cancer
Figure 15. Others
Figure 16. Cancer Immunotherapy Report Years Considered
Figure 17. Global Cancer Immunotherapy Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 18. Global Cancer Immunotherapy Market Size 2018-2034 (US$ Million)
Figure 19. Global Cancer Immunotherapy Market Size Market Share by Region: 2022 VS 2034
Figure 20. Global Cancer Immunotherapy Revenue Market Share by Region in 2018 VS 2022
Figure 21. Global Cancer Immunotherapy Revenue Market Share Forecast by Region (2024-2034)
Figure 22. Global Top 10 Cancer Immunotherapy Countries Ranking by Market Size (US$ Million) in 2022
Figure 23. Global Cancer Immunotherapy Market Size of Top 10 Countries, 2018 VS 2022 VS 2034, (US$ Million)
Figure 24. Global Cancer Immunotherapy Market Share by Players in 2022
Figure 25. Global Top Cancer Immunotherapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Immunotherapy as of 2022)
Figure 26. The Top 10 and 5 Players Market Share by Cancer Immunotherapy Revenue in 2022
Figure 27. North America Cancer Immunotherapy Revenue Market Share by Company in 2022
Figure 28. North America Cancer Immunotherapy Revenue Market Share by Type (2018-2034)
Figure 29. North America Cancer Immunotherapy Revenue Market Share by Application (2018-2034)
Figure 30. North America Cancer Immunotherapy Revenue Share by Country (2018-2034)
Figure 31. U.S. Cancer Immunotherapy Revenue (2018-2034) & (US$ Million)
Figure 32. Canada Cancer Immunotherapy Revenue (2018-2034) & (US$ Million)
Figure 33. Europe Cancer Immunotherapy Revenue Market Share by Company in 2022
Figure 34. Europe Cancer Immunotherapy Revenue Market Share by Type (2018-2034)
Figure 35. Europe Cancer Immunotherapy Revenue Market Share by Application (2018-2034)
Figure 36. Europe Cancer Immunotherapy Revenue Share by Country (2018-2034)
Figure 37. Germany Cancer Immunotherapy Revenue (2018-2034) & (US$ Million)
Figure 38. France Cancer Immunotherapy Revenue (2018-2034) & (US$ Million)
Figure 39. U.K. Cancer Immunotherapy Revenue (2018-2034) & (US$ Million)
Figure 40. Italy Cancer Immunotherapy Revenue (2018-2034) & (US$ Million)
Figure 41. Russia Cancer Immunotherapy Revenue (2018-2034) & (US$ Million)
Figure 42. Asia Pacific Cancer Immunotherapy Revenue Market Share by Company in 2022
Figure 43. Asia Pacific Cancer Immunotherapy Revenue Market Share by Type (2018-2034)
Figure 44. Asia Pacific Cancer Immunotherapy Revenue Market Share by Application (2018-2034)
Figure 45. Asia Pacific Cancer Immunotherapy Revenue Share by Region (2018-2034)
Figure 46. China Cancer Immunotherapy Revenue (2018-2034) & (US$ Million)
Figure 47. Japan Cancer Immunotherapy Revenue (2018-2034) & (US$ Million)
Figure 48. South Korea Cancer Immunotherapy Revenue (2018-2034) & (US$ Million)
Figure 49. India Cancer Immunotherapy Revenue (2018-2034) & (US$ Million)
Figure 50. Australia Cancer Immunotherapy Revenue (2018-2034) & (US$ Million)
Figure 51. Taiwan Cancer Immunotherapy Revenue (2018-2034) & (US$ Million)
Figure 52. Indonesia Cancer Immunotherapy Revenue (2018-2034) & (US$ Million)
Figure 53. Thailand Cancer Immunotherapy Revenue (2018-2034) & (US$ Million)
Figure 54. Malaysia Cancer Immunotherapy Revenue (2018-2034) & (US$ Million)
Figure 55. Philippines Cancer Immunotherapy Revenue (2018-2034) & (US$ Million)
Figure 56. Vietnam Cancer Immunotherapy Revenue (2018-2034) & (US$ Million)
Figure 57. Latin America Cancer Immunotherapy Revenue Market Share by Company in 2022
Figure 58. Latin America Cancer Immunotherapy Revenue Market Share by Type (2018-2034)
Figure 59. Latin America Cancer Immunotherapy Revenue Market Share by Application (2018-2034)
Figure 60. Latin America Cancer Immunotherapy Revenue Share by Country (2018-2034)
Figure 61. Mexico Cancer Immunotherapy Revenue (2018-2034) & (US$ Million)
Figure 62. Brazil Cancer Immunotherapy Revenue (2018-2034) & (US$ Million)
Figure 63. Argentina Cancer Immunotherapy Revenue (2018-2034) & (US$ Million)
Figure 64. Middle East and Africa Cancer Immunotherapy Revenue Market Share by Company in 2022
Figure 65. Middle East and Africa Cancer Immunotherapy Revenue Market Share by Type (2018-2034)
Figure 66. Middle East and Africa Cancer Immunotherapy Revenue Market Share by Application (2018-2034)
Figure 67. Middle East and Africa Cancer Immunotherapy Revenue Share by Country (2018-2034)
Figure 68. Turkey Cancer Immunotherapy Revenue (2018-2034) & (US$ Million)
Figure 69. Saudi Arabia Cancer Immunotherapy Revenue (2018-2034) & (US$ Million)
Figure 70. U.A.E Cancer Immunotherapy Revenue (2018-2034) & (US$ Million)
Figure 71. Amgen Revenue Growth Rate in Cancer Immunotherapy Business (2018-2024)
Figure 72. AstraZeneca Revenue Growth Rate in Cancer Immunotherapy Business (2018-2024)
Figure 73. Roche Revenue Growth Rate in Cancer Immunotherapy Business (2018-2024)
Figure 74. Bayer Revenue Growth Rate in Cancer Immunotherapy Business (2018-2024)
Figure 75. Bristol-Myers Squibb Revenue Growth Rate in Cancer Immunotherapy Business (2018-2024)
Figure 76. Eli Lilly Revenue Growth Rate in Cancer Immunotherapy Business (2018-2024)
Figure 77. Merck Revenue Growth Rate in Cancer Immunotherapy Business (2018-2024)
Figure 78. Novartis Revenue Growth Rate in Cancer Immunotherapy Business (2018-2024)
Figure 79. Pfizer Revenue Growth Rate in Cancer Immunotherapy Business (2018-2024)
Figure 80. Bottom-up and Top-down Approaches for This Report
Figure 81. Data Triangulation
Figure 82. Key Executives Interviewed